Home Tags Tripple negative beast cancer

Tag: tripple negative beast cancer

Updated Phase I Data for Ladiratuzumab Vedotin in Patients with Triple...

Data from an ongoing phase I clinical trial evaluating ladiratuzumab vedotin, also known as SGN-LIV1A, in patients with metastatic triple negative breast cancer presented...

Ladiratuzumab Vedotin (SGN-LIV1A) in Triple Negative Breast Cancers Shows a 29%...

Updated data from an ongoing Phase I clinical trial evaluating ladiratuzumab vedotin (SGN-LIV1A) in patients with metastatic triple negative breast cancer (mTNBC), was presented...

Biparatopic HER2-targeting Antibody-drug Conjugate Demonstrates Potent Antitumor Activity

HER2-targeted therapies have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of breast cancer.  Being overexposed in 20-25% of human breast cancers...